



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

# Advisory Committee on Vaccines

**Meeting Statement 33 – Friday 20 May 2022**

## **Section A: Submissions for registration**

The committee provided advice on two applications:

- Major variation (booster dose for individuals aged 12 years and over) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Spikevax; active ingredient elasomeran [mRNA]; sponsor Moderna Australia Pty Ltd) that had been under evaluation from March 2022
- Major variation (booster dose for individuals aged 18 years and over) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; sponsor Bioelect Pty Ltd) that had been under evaluation from March 2022.

Details of the ACV advice associated with these premarket items has been or will be released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see [AusPAR search](#).

## **Section B: Safety**

The committee was not asked to provide advice on any safety matter.

## **Further information**

For further information on the ACV, please visit [Advisory Committee on Vaccines](#) or contact the ACV by email [ACV@health.gov.au](mailto:ACV@health.gov.au).